within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AG08_Ocrelizumab;

model Ocrelizumab
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 1.967592592592593e-09,
    adminDuration = 600,
    adminMass = 600 / 1000000,
    adminCount = 1,
    Vd = 0.00311,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.00249,
    k12 = 3.3564814814814817e-09,
    k21 = 3.3564814814814817e-09);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Ocrelizumab</td></tr><tr><td>ATC code:</td><td>L04AG08</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>600</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>3.11</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.17</td><td>L/day</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Ocrelizumab is a humanized monoclonal antibody targeting CD20-positive B-cells, used for the treatment of relapsing and primary progressive forms of multiple sclerosis (MS). It is approved by regulatory agencies including the FDA and EMA.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetic data in adult MS patients, both sexes, typically aged 18-55 years, with normal renal and hepatic function.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L04AG08 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Ocrelizumab;
